middle.news
EVE Health Advances Libbo Pilot Study and Apixaban Solubility Breakthrough
9:47am on Friday 31st of July, 2026 AEST
•
Life Sciences
Read Story
EVE Health Advances Libbo Pilot Study and Apixaban Solubility Breakthrough
9:47am on Friday 31st of July, 2026 AEST
Key Points
Libbo pilot study protocol finalised with dosing expected Q4 2026
Apixaban solubility improved over 80-fold using proprietary technology
Ben Rohr appointed CEO to sharpen commercial execution
Net operating cash outflow of $465,000 with $1.24 million cash reserves
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Eve Health (ASX:EVE)
OPEN ARTICLE